US NIPD Market Growth Potential Examined in New Insightful Study Now Available at MarketPublishers.com

Share Article

New research study “US Non-Invasive Prenatal Diagnostics - Market Insight” drawn up by RNCOS has been recently published by Market Publishers Ltd. The study states that today the US NIPD sector is characterized by the presence of the companies that are effectively promoting their LDTs among the US population, especially targeting physicians to recommend their products.

TD The Market Publishers Ltd

http://marketpublishers.com/

Though being in its nascent stage of development, the non-invasive prenatal diagnostics (NIPD) segment presents a lucrative growth potential to a host of industry participants. The segment is chiefly supported by rising incidences of fetal health-related abnormalities and the urgent need for safe, accurate and early diagnosis. Products such as MaterniT21 Plus, Verifi, and Harmony prenatal tests are the current tests available in the market.

To date, the US NIPD sector is characterized by the presence of the companies that are effectively promoting their LDTs among the US population, especially targeting physicians to recommend their products. In future, the launch of Natera’s test is expected to impact the market significantly, thereby boosting the potential size and sample volume.

New research study “US Non-Invasive Prenatal Diagnostics - Market Insight” drawn up by RNCOS has been recently published by Market Publishers Ltd.

Report Details:

Title: US Non-Invasive Prenatal Diagnostics - Market Insight
Published: August, 2012
Pages: 60
Price: US$ 1,200.00
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/us_non_invasive_prenatal_diagnostics_market_insight.html

The report provides in-depth analysis of the current and future of the US non-invasive prenatal diagnostics market. A special emphasis is placed on a thorough analysis of the present regulatory framework by illustrating the views of regulatory authorities, players and consumers towards the regulatory stringency and the direction of regulations in the future. Clinical trials in the NIPD field through an active participation of public and private players are provided to assess the research and innovation. Furthermore, the study features the competitive landscape in the US non-invasive prenatal diagnostics market as well as analyzes the top market players through an overview of their products as well as an assessment of their strengths & weaknesses.

Companies discussed include: Ariosa Diagnostics, Sequenom, Verinata, Natera, and Fluidigm.

Report Contents:

1. Analyst View

2. Research Methodology

3. Statistical Snapshot - Pregnancies and Chromosomal Abnormalities

4. Overview of US Prenatal Diagnostics Market

4.1 Introduction
4.2 Prenatal Diagnostics Industry
4.2.1 Preliminary Prenatal Testing
4.2.2 First Trimester Screening
4.2.3 Second Trimester Screening
4.2.4 Chorionic Villus Sampling (CVS) Testing
4.2.5 Amniocentesis Testing

5. US Non-Invasive Prenatal Diagnostics - Market Insight

5.1 Tests Available in the Market
5.1.1 MaterniT21 (Sequenom)
5.1.2 Verifi (Verinata)
5.1.3 Harmony Prenatal Test (Ariosa Diagnostics)
5.2 Current and Future Market Projections to 2016
5.3 Regulatory Insight
5.3.1 Current Regulatory Scenario
5.3.2 Regulatory Authority Perspective
5.3.3 Diagnostic Test Provider Perspective
5.3.4 Consumers’ Perspective
5.3.5 Analyst Inputs

6. Current Technologies in the Market

7. Projects in Clinical Trials

8. Constraints in NIPD Market

9. Competitive Assessment

9.1 Ariosa Diagnostics
9.1.1 Company Overview
9.1.2 Product Overview
9.1.3 Strengths & Weaknesses
9.2 Sequenom
9.2.1 Company Overview
9.2.2 Product Overview
9.2.3 Strengths and Weaknesses
9.3 Verinata
9.3.1 Company Overview
9.3.2 Product Overview
9.3.3 Strengths and Weaknesses
9.4 Natera
9.4.1 Company Overview
9.4.2 Product Overview
9.4.3 Strengths and Weaknesses
9.5 Fluidigm
9.5.1 Company Overview
9.5.2 Product Overview
9.5.3 Strengths and Weaknesses

List of Figures

Figure 3-1: Population Base (Million), 2000-2010
Figure 4-1: Prenatal Testing Market (Billion US$), 2012-2016
Figure 4-2: Preliminary Prenatal Testing Market (Million US$), 2012-2016
Figure 4-3: First Trimester Screening Market (Million US$), 2012-2016
Figure 4-4: Second Trimester Screening Market (Million US$), 2012-2016
Figure 4-5: CVS Testing Market (Million US$), 2012-2016
Figure 4-6: Amniocentesis Testing Market (Million US$), 2012-2016
Figure 5-1: Non-Invasive Prenatal Diagnostics Market (Million US$), 2012-2016
Figure 5-2: Share of Players in Number of NIPD Tests Performed (2012)
Figure 5-3: Share of Players in NIPD Market (2012)
Figure 5-4: Forecast for Share of Players in Number of NIPD Tests Performed (2016)
Figure 5-5: Forecast for Share of Players in NIPD Market (2016)
Figure 5-6: Laboratorians’ Attitudes towards FDAs Regulations on Lab Developed Tests (LDT)

List of Tables

Table 3-1: Number of Births and Abortions (2000-2010)
Table 3-2: Number of Multiple Pregnancies (2000-2009)
Table 3-3: Prevalence of Chromosomal Abnormalities
Table 4-1: Major Preliminary Prenatal Tests Performed
Table 4-2: Major First Trimester Screening Tests Performed
Table 4-3: Major Second Trimester Screening Tests Performed
Table 5-1: Inter-comparison of CLIA and FDA Regulatory Pathway
Table 6-1: Common Commercial Kits and Protocols for Isolation of ccff DNA from Maternal Plasma
Table 7-1: Key undergoing Non-invasive Prenatal Diagnostic (NIPD) Studies

More new market research studies by the publisher can be found at RNCOS page.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website